Department of Women's and Children's Health, Uppsala University, Uppsala, SwedenChild and Adolescent Habilitation Centre, County Council of Uppsala, Uppsala, SwedenDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, SwedenDepartment of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Acta Paediatr. 2010 May;99(5):763-769. doi: 10.1111/j.1651-2227.2009.01679.x. Epub 2010 Jan 25.
Down syndrome (DS) is associated with short stature and psychomotor delay. We have previously shown that growth hormone (GH) treatment during infancy and childhood normalizes growth velocity and improves fine motor skill performance in DS. The aim of this study was to investigate late effects of early GH treatment on growth and psychomotor development in the DS subjects from the previous trial.
Twelve of 15 adolescents with DS (3 F) from the GH group and 10 of 15 controls (5 F) participated in this follow-up study. Fifteen other subjects with DS (6 F) were included as controls in anthropometric analyses. Cognitive function was assessed with the Leiter International Performance Scale-Revised (Leiter-R) and selected subtests of the Wechsler Intelligence Scale for Children, Third edition (WISC-III). The Bruininks-Oseretsky Test of Motor Proficiency, Second edition (BOT-2), was used to assess general motor ability.
Although early GH treatment had no effect on final height, the treated subjects had a greater head circumference standard deviation score (SDS) than the controls (-1.6 SDS vs. -2.2 SDS). The adolescents previously treated with GH had scores above those of the controls in all subtests of Leiter-R and WISC-III, but no difference in Brief IQ-score was seen between the groups. The age-adjusted motor performance of all subjects was below -2 SD, but the GH-treated subjects performed better than the controls in all but one subtest.
The combined finding of a greater head circumference SDS and better psychomotor performance indicates that DS subjects may benefit from early GH treatment.
唐氏综合征(DS)与身材矮小和精神运动发育迟缓有关。我们之前已经表明,婴儿期和儿童期的生长激素(GH)治疗可使 DS 患者的生长速度正常化,并改善精细运动技能表现。本研究的目的是调查先前试验中 GH 治疗对 DS 受试者生长和精神运动发育的后期影响。
来自 GH 组的 15 名青少年 DS 患者中有 12 名(3 名女性)和 15 名对照组中有 10 名(5 名女性)参与了这项随访研究。另外 15 名 DS 患者(6 名女性)作为对照组纳入了人体测量分析。认知功能采用 Leiter 国际表现量表修订版( Leiter-R)和韦氏儿童智力量表第三版(WISC-III)的部分测验进行评估。Bruininks-Oseretsky 运动能力测验,第二版(BOT-2)用于评估一般运动能力。
尽管早期 GH 治疗对最终身高没有影响,但治疗组的头围标准差评分(SDS)高于对照组(-1.6 SDS 与-2.2 SDS)。与对照组相比,先前接受 GH 治疗的青少年在 Leiter-R 和 WISC-III 的所有子测验中的得分均高于对照组,但两组之间的简要智商得分无差异。所有受试者的年龄调整后的运动表现均低于-2 SD,但 GH 治疗组在除一项子测验外的所有子测验中的表现均优于对照组。
头围 SDS 较大和精神运动表现较好的综合发现表明,DS 患者可能受益于早期 GH 治疗。